Cabot Wealth Management Inc. reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 3.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,548 shares of the company’s stock after selling 1,077 shares during the quarter. Medpace comprises about 1.4% of Cabot Wealth Management Inc.’s investment portfolio, making the stock its 24th biggest position. Cabot Wealth Management Inc. owned 0.10% of Medpace worth $14,060,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the fourth quarter valued at about $30,000. Allied Private Wealth LLC acquired a new stake in Medpace during the 2nd quarter valued at approximately $31,000. Basecamp Wealth Advisors LLC increased its stake in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after buying an additional 45 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of Medpace in the 3rd quarter worth about $35,000. Institutional investors and hedge funds own 77.98% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the stock. Mizuho increased their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and upped their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. TD Cowen boosted their price target on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a research report on Thursday, July 23rd. Finally, Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $584.18.
Medpace Trading Down 0.6%
Shares of Medpace stock opened at $578.50 on Friday. The stock has a market capitalization of $16.15 billion, a price-to-earnings ratio of 33.91, a PEG ratio of 2.60 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The business’s 50 day simple moving average is $536.23 and its 200-day simple moving average is $492.35.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.
Insider Activity
In other news, Director Cornelius P. Mccarthy III sold 1,140 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the transaction, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO August J. Troendle sold 17,610 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the transaction, the chief executive officer owned 615,802 shares of the company’s stock, valued at $372,627,948.22. This represents a 2.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is owned by insiders.
Medpace Company Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
- Five stocks we like better than Medpace
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
